Physician profile
Gustavo Henrique Boff Maegawa
NPI 1366671380
$42,753.25
in general payments reported to CMS, 2019-2025
8 companies · $9,436 in 2025
The $9,436 reported for 2025 was more than what 99% of Clinical Biochemical Genetics providers received nationally (typical 2025 total: $237).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22.66 · 2021: $11K · 2022: $3,613 · 2023: $13K · 2024: $4,981 · 2025: $9,436.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $21K · Honoraria: $3,880 · Travel and Lodging: $1,661 · Food and Beverage: $822.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $21,444.25 |
| Honoraria | $3,880.00 |
| Travel and Lodging | $1,660.54 |
| Food and Beverage | $821.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $15,512.92 | 2023-2025 | |
| Sanofi US Services INC. | $14,965.50 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $5,526.25 | 2023-2025 | Elaprase |
| Chiesi USA, INC. | $4,824.72 | 2024 | Lamzede, Elfabrio |
| Amicus Therapeutics, INC. | $1,794.68 | 2019-2024 | Opfolda, Pombiliti |
| Biomarin Pharmaceutical INC. | $79.18 | 2025 | Brineura |
| Alexion Pharmaceuticals, INC. | $27.78 | 2025 | |
| Duchesnay USA Incorporated | $22.22 | 2023 | Pheburane |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gustavo Maegawa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.